Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
The European Respiratory Journal|March 23, 2013
Add-on omalizumab in children with severe allergic asthma: a 1-year real life surveyAntoine Deschildre, Christophe Marguet, Julia Salleron, et al.
The Journal of Antimicrobial Chemotherapy|October 25, 2020
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimenRomain Palich, Clotilde Allavena, Gilles Peytavin, et al.
AIDS (London, England)|August 11, 2020
HIV infection and COVID-19: risk factors for severe diseaseNicolas Etienne, Marina Karmochkine, Laurence Slama, et al.
AIDS (London, England)|January 31, 2003
Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trialYves Levy, Christine Durier, Roman Krzysiek, et al.
The Journal of Clinical Investigation|April 5, 2022
Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV controlFederico Perdomo-Celis, Caroline Passaes, Valérie Monceaux, et al.
Plos One|August 10, 2016
Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 ParticlesChiraz Hamimi, Annie David, Pierre Versmisse, et al.
Pharmacotherapy|March 1, 2019
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL StudyMinh Patrick Lê, Marc-Antoine Valantin, Lambert Assoumou, et al.
The Journal of Clinical Investigation|March 17, 2009
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatmentYves Levy, Christine Lacabaratz, Laurence Weiss, et al.
AIDS Research and Human Retroviruses|October 22, 2024
"They Have to Make an Effort Too": What Decliners Can Teach Us About HIV Cure/Remission-Related Clinical Trials? Results from a French Qualitative StudySarah Lefebvre, Jean-Daniel Lelièvre, Véronique Rieux, et al.
The Journal of Infectious Diseases|December 13, 2019
Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIVDominique Costagliola, Valérie Potard, Sylvie Lang, et al.
Pageof 14